KVX‑053: targeting microvascular leakage and inflammation
What it is: KVX 053 is a first in class, host directed small molecule that stabilizes the endothelial barrier to prevent microvascular leakage, reduce inflammation, and restore lung function/mechanics. It targets PTP4A3, a key regulator of vascular permeability and inflammatory signaling. KVX-053 is also agnostic to the acute lung injury trigger (i.e., virus, bacteria, chemical exposure, mechanical trauma).
Why it matters: Microvascular leakage is a central driver of morbidity and mortality in acute lung injury, ARDS, chemical inhalation exposures, and other high need, acute respiratory conditions. Current treatments address symptoms or downstream inflammation but do not repair the endothelial barrier itself. KVX 053 directly addresses this upstream unmet need, offering a broad therapeutic opportunity — a pipeline in a product — across multiple acute lung indications.
How it works: KVX 053 inhibits PTP4A3 to stabilize endothelial junctions, reduce vascular leak, and suppress inflammatory cascades. By repairing the endothelial barrier, KVX 053 prevents edema, improves oxygenation, and reduces tissue injury across diverse insults. This mechanism is host directed, making it applicable to chemical exposures, infectious triggers, and inflammatory injury.
Proof to date: KVX 053 demonstrates strong in vivo efficacy across multiple lung injury models. Studies show reduced vascular leakage, improved lung function, and decreased inflammatory signaling. Early toxicology and PK/PD data support a favorable safety profile. The program is currently advancing through IND enabling development, including GLP toxicology, clinical formulation optimization, and CMC characterization.
Next steps: KeViRx is completing IND enabling studies and preparing for regulatory engagement to support a first in human Phase 1 trial. We are seeking partners for sponsored research, indication expansion studies, formulation and delivery optimization, and strategic collaborations.
About KeViRx, Inc.
KeViRx, Inc. is a Charlottesville, Virginia-based biotechnology company founded in 2016 that focuses on the development of small molecule therapeutics for treating microvascular leakage and inflammation. The company's platform technology, centered on its lead asset KVX-053, is designed to heal the endothelial lining within blood vessels and regenerate lung cell connections. Unlike conventional treatments that target specific pathogens, KeViRx’s approach is host-directed, aiming to address the underlying cellular damage that contributes to acute lung injury, which can be caused by viral infections, sepsis, bacterial pneumonia, or chemical inhalation.
This technology is critical for patients in intensive care settings who may otherwise rely on mechanical ventilation, which can exacerbate lung damage. By repairing the root causes of inflammation and restoring lung function, KVX-053 aims to improve patient recovery and reduce reliance on invasive respiratory support. The company’s research has shown efficacy in various preclinical models of lung injury and cancer. Supported by non-dilutive funding, including grants from the U.S. Department of Defense and membership in the Blue Knight collaboration, KeViRx is actively advancing its lead compound toward clinical trials.
delivered to your inbox.